Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(87 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(79 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(26 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1372 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DMH4
CAS:<p>DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 µM.</p>Fórmula:C24H24N4O2Pureza:99.58%Cor e Forma:SolidPeso molecular:400.47Spebrutinib besylate
CAS:<p>Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).</p>Fórmula:C28H28FN5O6SPureza:98%Cor e Forma:SolidPeso molecular:581.62Sovleplenib
CAS:<p>Sovleplenib (HMPL-523), oral SYK inhibitor, IC50 25 nM, targets tumors & ITP studies.</p>Fórmula:C24H30N6O3SPureza:99.71%Cor e Forma:SolidPeso molecular:482.6ER-27319
CAS:<p>ER-27319, an acridone derivative, serves as a potent and selective inhibitor of spleen tyrosine kinase (SYK), effectively impeding both the tyrosine</p>Fórmula:C20H22N2O5Pureza:98%Cor e Forma:SolidPeso molecular:370.4FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Cor e Forma:SolidPeso molecular:431.49EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Cor e Forma:SolidPeso molecular:265.26c-Fms-IN-9
CAS:<p>c-Fms-IN-9 inhibits c-FMS/uFMS and uKIT with IC50 <0.01μM and 0.1-1μM, from patent WO2014145023A1.</p>Fórmula:C21H23N7O2Pureza:98%Cor e Forma:SolidPeso molecular:405.45Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Cor e Forma:SolidPeso molecular:461.74EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Cor e Forma:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Cor e Forma:SolidPeso molecular:480.95EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Cor e Forma:SolidPeso molecular:348.4Ansornitinib
CAS:<p>Ansornitinib (ANG-3070) is a KDR and PDGF receptor inhibitor with antifibrotic activity for the study of diseases caused by abnormal or excessive fibrosis.</p>Fórmula:C30H32N6O4Cor e Forma:SolidPeso molecular:540.61JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Cor e Forma:SolidPeso molecular:543.61IACS-9439
CAS:<p>IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM.</p>Fórmula:C23H26ClN7O3SPureza:98%Cor e Forma:SolidPeso molecular:516.02TG-46
CAS:<p>TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.</p>Fórmula:C26H34N6O3SPureza:98.82% - 99.81%Cor e Forma:SolidPeso molecular:510.65PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Cor e Forma:SolidPeso molecular:441.27EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Fórmula:C16H16BrN3OPureza:98% - 99.6%Cor e Forma:SolidPeso molecular:346.22DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Cor e Forma:SolidPeso molecular:389.45(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Cor e Forma:SolidPeso molecular:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Cor e Forma:SolidPeso molecular:274.32EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Cor e Forma:SolidPeso molecular:571.69EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OCor e Forma:SolidPeso molecular:354.44EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SCor e Forma:SolidPeso molecular:287.34c-Kit-IN-2
CAS:<p>c-Kit-IN-2 is a c-KIT inhibitor (IC50: 82 nM), shows superior antiproliferative activities against all the three GIST cell lines, GIST430, GIST882, and GIST48 (</p>Fórmula:C25H29N9O2SPureza:98%Cor e Forma:SolidPeso molecular:519.62Lanraplenib monosuccinate
CAS:<p>Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.</p>Fórmula:C27H31N9O5Pureza:98%Cor e Forma:SolidPeso molecular:561.59Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Cor e Forma:SolidPeso molecular:359.42EAI001
CAS:<p>EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.</p>Fórmula:C19H15N3O2SPureza:>99.99%Cor e Forma:SolidPeso molecular:349.41Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Cor e Forma:SolidPeso molecular:591.12RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Cor e Forma:SolidPeso molecular:510.96MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SCor e Forma:SolidPeso molecular:1056.72EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Cor e Forma:SolidPeso molecular:526.42JAK-IN-21
CAS:<p>JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.</p>Fórmula:C19H16N8OPureza:99.75%Cor e Forma:SolidPeso molecular:372.38EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SCor e Forma:SolidPeso molecular:413.45Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Cor e Forma:SolidPeso molecular:565.06AXL-IN-13
CAS:<p>AXL-IN-13: potent, oral AXL inhibitor, IC50=1.6nM, Kd=0.26nM, anti-cancer, inhibits EMT, cell migration & invasion.</p>Fórmula:C34H41FN6O5Pureza:99.20%Cor e Forma:SolidPeso molecular:632.72CE-245677 mesylate
CAS:<p>CE-245677 mesylate is a selective Tie2 kinase inhibitor with oral activity and potential anti-tumor effects, useful in pain research.</p>Fórmula:C25H26Cl2N6O6SPureza:99.42%Cor e Forma:SolidPeso molecular:609.48c-Kit-IN-3
CAS:<p>c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I).</p>Fórmula:C26H20ClF3N2O4Pureza:99.94%Cor e Forma:SolidPeso molecular:516.9FLT3-IN-4
CAS:<p>FLT3-IN-4 (FLT3 inhibitor 9u) is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor ,for treating acute myelogenous</p>Fórmula:C23H25N7O2Pureza:99.9%Cor e Forma:SolidPeso molecular:431.49SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Cor e Forma:SolidPeso molecular:316.35EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Cor e Forma:SolidPeso molecular:569.67CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Cor e Forma:SolidPeso molecular:355.82RU-302
CAS:<p>RU-302 is a pan inhibitor of TAM Receptor blocking the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain.</p>Fórmula:C24H24F3N3O2SPureza:99.84%Cor e Forma:SolidPeso molecular:475.53AMG-Tie2-1
CAS:<p>AMG-Tie2-1 is a Tie2 and VEGFR2 inhibitor with anticancer and antitumor activity for the study of cardiovascular disease and cancer.</p>Fórmula:C25H20F3N5O2Pureza:98.9%Cor e Forma:SolidPeso molecular:479.45OXSI-2
CAS:<p>OXSI-2 (Syk Inhibitor) is an inhibitor of Syk with an EC50 of 313 nM and an IC50 of 14 nM.</p>Fórmula:C18H15N3O3SPureza:98%Cor e Forma:Dark Orange SolidPeso molecular:353.39EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Cor e Forma:SolidPeso molecular:551.66EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SCor e Forma:SolidPeso molecular:658.64RO9021
CAS:<p>RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).</p>Fórmula:C18H25N7OPureza:97.19%Cor e Forma:SolidPeso molecular:355.44EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Cor e Forma:SolidPeso molecular:453.49CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Cor e Forma:SolidPeso molecular:329.35EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Cor e Forma:SolidPeso molecular:538.64
